TG Therapeutics (TGTX) Is Up 10.4% After Launching Phase 3 Trial of Subcutaneous BRIUMVI—Has The Bull Case Changed?

• TG Therapeutics recently began enrolling patients in a Phase 3 clinical trial to evaluate a new subcutaneous formulation of BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis, adding to its approved intravenous product portfolio.
• This milestone highlights the company's efforts to expand its reach in the multiple sclerosis market and address patient convenience with alternative modes of administration.
• We'll now explore how launching a subcutaneous BRIUMVI could reshape TG Therapeutics' growth narrative and long-term revenue outlook.

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

TG Therapeutics Investment Narrative Recap

To be a TG Therapeutics shareholder today, you need to believe in BRIUMVI’s ability to capture greater share in the multiple sclerosis market as the company pursues new formulations and addresses shifting patient and prescriber preferences. The start of the Phase 3 subcutaneous BRIUMVI trial reinforces the company's response to increasing demand for self-administered therapies, directly supporting its most important near-term catalyst; however, the largest risk, intense pricing pressure and competition from established and emerging anti-CD20 and self-administered therapies, remains firmly in place and is not meaningfully reduced by this news.

Among recent announcements, the launch of the $100 million share repurchase program stands out. While not directly related to the new clinical trial, it signals management’s confidence and could temporarily support the share price as investors watch for progress on the subcutaneous BRIUMVI rollout.

But on the flipside, investors should pay particular attention to how margin pressures and payer demands for lower-cost, self-administered therapies could still weigh on future...

Read the full narrative on TG Therapeutics (it's free!)

TG Therapeutics' outlook anticipates $1.2 billion in revenue and $469.0 million in earnings by 2028. This requires annual revenue growth of 39.5% and an increase in earnings of $408.5 million from the current level of $60.5 million.

Uncover how TG Therapeutics' forecasts yield a $40.50 fair value, a 25% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members value TG Therapeutics from as low as US$23.49 up to US$139.06, with four independent estimates. Diverging forecasts like these remind you to consider how market shifts toward self-administered MS treatments might affect both near and long-term performance.

Explore 4 other fair value estimates on TG Therapeutics - why the stock might be worth 27% less than the current price!

Build Your Own TG Therapeutics Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your TG Therapeutics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Curious About Other Options?

Our top stock finds are flying under the radar-for now. Get in early:

• Outshine the giants: these 27 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com